SAR422459

DRUG2 trials

Sponsors

Sanofi-Aventis Recherche & Developpement, Sanofi

Conditions

CongenitalStargardt's Diseasehereditary and neonatal diseases

Phase 1

Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration

TerminatedNCT01367444

SanofiStargardt's Disease

Start: 2011-06-08End: 2019-08-16Updated: 2022-04-14

Phase 2

An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients with Stargardt’s Macular Degeneration

Active, not recruitingCTIS2024-513501-31-00

Sanofi-Aventis Recherche & DeveloppementCongenital, hereditary and neonatal diseases

Start: 2013-05-30Target: 14Updated: 2024-08-13

Related Papers

Test-Retest Variability of Functional and Structural Parameters in Patients with Stargardt Disease Participating in the SAR422459 Gene Therapy Trial.

2016-10-0135 citations

Gene therapy for Stargardt disease

Acta Ophthalmologica2014-08-20